In R&D, we are developing new platform drug delivery technologies as well as difficult-to-formulate generic products in both solid and liquid oral dosage forms. Our focus in on the development of NDA and ANDA products using existing molecules in new dosage forms or via new routes of administration. We have the capability to deliver reproducible bench-level experiments and submission batches and take them to commercial scale. We also internally conduct analytical testing, including method development, validation, release, and stability. Our objective is to improve patient compliance, better the safety and efficacy profile of our products, and extend the product life cycle.